CELLINK AB (publ) (“CELLINK”) has entered into an agreement with the owners of Scienion AG (“Scienion”), a German life science company focusing on precision dispensing technologies, to acquire all shares for a purchase price on cash- and debt-free basis of 80 M euros (the “Acquisition”). 40 M euros will be paid in 2,814,032 newly issued shares of series B in CELLINK (the “Consideration Shares”) and the reminder in cash. CELLINK’s Board of Directors will resolve to issue the Consideration Shares in accordance with the authorization from the Annual General Meeting held on December 18, 2019.
CELLINK also contemplates to explore the conditions for raising additional equity through one directed share issue within the limit of CELLINK’s existing authorization to issue shares from the Extraordinary General Meeting held on July 16, 2020.
SCIENION AG, a leading solution provider for ultra-low volume liquid handling applications, today announced that its new subsidiary Cellenion SASU started operations in Lyon, France back in May 2016 and has just launched its new website. Cellenion focuses on controlled cell dispensing technologies in the fields of bioprinting and single-cell dispensing. The young company was already awarded with the prestigious BIOVISION Catalyzer Project award in April 2016.